| Objective:In order to explore the therapeutic effect and observe the short-term and long-term effects,the factors affecting the therapeutic effect and adverse reactions,the patients with advanced colorectal cancer were treated with recombinant human vascular endothelial inhibitor injection(Endostar)through continuous intravenous infusion and combined with window period chemotherapy.It may provide the basis for the optimal regimen of antivascular targeted drugs in the treatment of advanced colorectal cancer.Methods:1.We collected 60 patients with advanced colorectal cancer in our department of oncology from July 2015 to October 2017.The patients were divided into 3 groups:20 patients in group A(continuous intravenous infusion of endostar combined with window period chemotherapy),20 patients in the group B(intravenous drip of endostar combined with window period chemotherapy)and 20 patients in the group C(only chemotherapy alone).Chemotherapy was a two-week regimen and every four weeks was a course of treatment;chemotherapy was a three-week regimen and every three weeks was a course of treatment.Those patients were evaluated the efficacy after they received two and four courses of treatment,and adverse reactions were recorded.2.The patients were followed up by hospitalization,telephone follow-up and outpatient reexamination after discharge.The duration of follow-up was calculated from first day to October 31,2017.Patients began to receive treatment,which was regarded as the starting point of the study.The last treatment,follow-up and review were as the end of the study.3.The therapeutic effect index(CR,PR,SD and PD),progressive survival time(PFS),objective remission rate(ORR),disease control rate(DCR),quality of life(QOL)and toxicity in group A,B and C were recorded.The effect of continuous intravenous infusion of Endostar combined with window period chemotherapy on prognosis of patients with advanced colorectal cancer was analyzed by statistical analysis of PFS.4.SPSS 19.0 software was used for data analysis and statistics description.Results:All patients from three groups completed at least four treatment cycles.After two treatment cycles,objective remission rate(ORR)in A,B,C group was 50.0%,40.0%and 35.0%,respectively.Disease control rate(DCR)in A,B,C group was 90.0%,75.0%,65.0%,respectively.After the four courses of treatment,objective remission rate(ORR)in A,B,C group was 45.0%,35.0%and 30.0%,respectively.Disease control rate(DCR)in A,B,C group was 90.0%,70.0%,60.0%,respectively.There was no significant difference on adverse reactions between group A and group B,and there was no significant difference on adverse reactions between group B and group C(P>0.05).The median stage of no disease progression in group A was 4.9 months,that in group B was 3.2 months and that in group C was 2.1 months,respectively.The results showed that both group A and group B had significantly longer median non-disease progressive time than group C and the median time of disease free progression in group A was longer than that in group B.Conclusion:The treatment of advanced colorectal cancer though endostar durative transfusion combined with window phase chemotherapy has an obvious curative effect.1.Endostar durative transfusion is superior to the traditional intravenous drip and it can play a better role in anti-angiogenesis.2.Endostar durative transfusion can increase duration of mPFS compared to intravenous drip.3.Endostar combined with chemotherapy is more effective than chemotherapy alone in the treatment of advanced colorectal cancer.It is safe and has a good clinical significance,this treatment scheme is worth popularizing in clinic. |
PDF Full Text Request